Method for developing organ that lacks specific functional cell
Inventors
Nagashima, Hiroshi • MATSUNARI, Hitomi • Nakano, Kazuaki • Hasegawa, Koki
Assignees
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Abstract
Provided is a method for developing a secondary organ by using a non-human animal in which organ formation is inhibited, for the purpose of establishing a process for producing a functional cell such as a β cell within the body of an animal such as a pig, the method including the step of raising a newborn or a fetus of the non-human animal in which organ formation is inhibited by complementing at least a part of the function of the organ whose formation is inhibited.
Core Innovation
The document describes developing a secondary organ of a pancreas in a newborn non-human mammal in which pancreas formation is inhibited by expression of a heterologous nucleic acid encoding Hes1 operably linked to a Pdx1 promoter. In this setting, the developing secondary organ lacks formation of β cells and therefore does not form β-cell (insulin) production, while tissue components include glucagon-expressing cells and amylase-expressing cells.
The document further describes that formation of the pancreas-like secondary organ is promoted by administering insulin and a digestive enzyme to the newborn non-human mammal whose genome comprises the heterologous Hes1 nucleic acid under the control of the Pdx1 promoter. Through this supported raising, pancreas-like tissue emerges despite inhibited pancreas development, and the presence of glucagon and amylase-related tissue is observed while insulin-related β-cell formation is lacking.
In the described example, supported raising enables survival and emergence of pancreas-like tissue that can serve as a niche for establishing transplanted cells. The document reports that diabetic-like complications can occur in the β-cell-deficient animals, while the pancreas-like tissue is reduced in size and shows amylase production; glucagon is detected without insulin by immunostaining.
Claims Coverage
The provided claims identify three independent claim sets covering a method of developing a pancreas secondary organ, the resulting non-human animal, and the resulting secondary organ itself. Across the independent claims, the key inventive combination comprises Hes1 under a Pdx1 promoter that inhibits pancreas development together with administration of insulin and a digestive enzyme, yielding a β-cell-lacking organ that includes glucagon-expressing cells and amylase-expressing cells.
Insulin and digestive enzyme administration for Hes1/Pdx1 pancreas inhibition
Administering insulin and a digestive enzyme to a newborn non-human mammal whose genome comprises a heterologous nucleic acid encoding Hes1 operably linked to a Pdx1 promoter, wherein the administering promotes formation of a secondary organ that lacks formation of β cells and includes glucagon-expressing cells and amylase-expressing cells.
A non-human animal with a β-cell-lacking pancreas secondary organ from Hes1/Pdx1 inhibition plus administration
A non-human animal comprising a secondary organ of a pancreas lacking formation of β cells and including glucagon-expressing cells and amylase-expressing cells, wherein the animal is obtained by administering insulin and a digestive enzyme to a newborn non-human animal comprising a heterologous nucleic acid encoding Hes1 operably linked to a Pdx1 promoter, wherein development of a pancreas is inhibited by expression of said heterologous nucleic acid and the administering results in formation of said secondary organ in said newborn.
A pancreas secondary organ produced by Hes1/Pdx1 inhibition plus administration
A secondary organ of a pancreas lacking formation of β cells and including glucagon-expressing cells and amylase-expressing cells, wherein the secondary organ is obtained by administering insulin and a digestive enzyme to a newborn non-human animal comprising a heterologous nucleic acid encoding Hes1 operably linked to a Pdx1 promoter, wherein development of a pancreas is inhibited by expression of said heterologous nucleic acid and the administering results in formation of said secondary organ in said newborn.
Across the independent claims, the invention centers on preventing pancreas development via Hes1 expression under a Pdx1 promoter in a newborn non-human mammal and promoting the formation of a pancreas secondary organ by administering insulin and a digestive enzyme. The resulting secondary organ lacks formation of β cells and instead includes glucagon-expressing cells and amylase-expressing cells, and can serve as a niche for establishing transplanted cells.
Stated Advantages
Supported raising enables survival and emergence of pancreas-like tissue.
The pancreas-like tissue can serve as a niche for establishing transplanted cells.
Diabetic-like complications can occur in the β-cell-deficient animals.
The pancreas-like tissue is reduced in size and shows amylase production.
Glucagon is detected without insulin by immunostaining.
Documented Applications
No documented applications found
Interested in licensing this patent?